Reposted by Neil Rajan
Recombinant DNASE1L3 therapy reduced symptoms in a patient with severe lupus with DNASE1L3 deficiency. Antidrug antibodies caused effects to wane, but findings support NET-targeted therapy as a nonimmunosuppressive approach. Read the full report: nej.md/3Rlv5Sm